Forte Biosciences (FBRX) Interest Coverage Ratio (2016 - 2020)
Forte Biosciences (FBRX) posted quarterly Interest Coverage Ratio of 0.51 for Q1 2026, up 97.38% year-over-year from 0.26 in Q1 2025, and up 99.91% quarter-over-quarter from 571.42 in Q4 2025.
Powered by 
Analysis
Forte Biosciences (FBRX) Interest Coverage Ratio (2016 - 2020) Analysis & Trends
Forte Biosciences (FBRX) has reported Interest Coverage Ratio for 11 consecutive years, with 0.51 the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest Coverage Ratio rose 97.38% year-over-year to 0.51; the TTM figure through Mar 2026 stood at 1.76 (up 96.77% YoY), while the FY2025 annual figure was 1.5, changed 0.48% from the prior year.
- Interest Coverage Ratio improved to 0.51 in Q1 2026 per FBRX's latest filing, from 571.42 in the prior quarter.
- Across five years, Interest Coverage Ratio topped out at 0.51 in Q1 2026 and bottomed at 2043.2 in Q3 2023.
- Historically, Interest Coverage Ratio has averaged 253.17 across 5 years, with a median of 90.75 in 2024.
- Annual changes were most pronounced in 2023 — Interest Coverage Ratio plunged 5749.65% — and 2025, when it jumped 99.8%.
- Forte Biosciences' Interest Coverage Ratio stood at 75.98 in 2022, then sank by 179.93% to 212.7 in 2023, then soared by 57.33% to 90.75 in 2024, then plunged by 529.64% to 571.42 in 2025, then jumped by 99.91% to 0.51 in 2026.
- Business Quant data shows FBRX's Interest Coverage Ratio at 0.51 in Q1 2026, 571.42 in Q4 2025, and 1.06 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.87 Bn | 131.01 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.57 Bn | 77.57 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | -493.00 |
| 4 | Moderna | 58.19 Bn | 53.05 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.07 Bn | 44.07 Bn | - | -21.24 |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn | 8.18 |
| 7 | Alnylam Pharmaceuticals | 35.38 Bn | 32.07 Bn | 992.69 Mn | 2.82 |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | 1.42 |
| 9 | Insmed | 27.41 Bn | 26.25 Bn | 358.27 Mn | -0.08 |
| 10 | Forte Biosciences | 1.58 Bn | 1.23 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2020 | -2.68 |
| Dec 31, 2019 | -4.74 |
| Sep 30, 2019 | -0.35 |
| Jun 30, 2019 | -0.82 |
| Mar 31, 2019 | -22.38 |
| Dec 31, 2018 | -25.61 |
| Sep 30, 2018 | 1.92 |
| Jun 30, 2018 | -14.02 |
| Mar 31, 2018 | -36.81 |
| Dec 31, 2017 | -27.33 |
| Sep 30, 2017 | -22.64 |
| Jun 30, 2017 | -17.48 |
| Mar 31, 2017 | -13.88 |
| Dec 31, 2016 | -14.96 |
| Sep 30, 2016 | -16.69 |
| Jun 30, 2016 | -15.09 |
| Mar 31, 2016 | -15.04 |